[Skip to Navigation]
Sign In
Comment & Response
February 24, 2022

Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer—Reply

Author Affiliations
  • 1University of California, San Francisco
  • 2University of Texas MD Anderson Cancer Center, Houston
JAMA Oncol. 2022;8(4):645-646. doi:10.1001/jamaoncol.2021.8000

In Reply Thank you to Drs Huang and Liu for their thoughtful comments on our analysis of a randomized clinical trial evaluating the relationship between residual cancer burden (RCB) and event-free survival in the I-SPY2 trial.1 They raise the point that local therapy received may influence recurrence events, as prior reports have shown an increased risk of locoregional recurrence in patients receiving neoadjuvant chemotherapy.2 Additionally, they suggest incorporation of stromal features into prognostic tools, such as RCB.

Add or change institution